Nastech starts dosing in study of PYY(3-36) for obesity

By Lisa Kerner

Charlotte, N.C., Aug. 14 - Nastech Pharmaceutical Co. Inc. said it began a dose ranging study to evaluate the pharmacokinetics, appetite, food intake and safety of various doses of Nastech's proprietary PYY(3-36) nasal spray in 12 subjects having a Body Mass Index of 30-40 kg/m(2) (obese).

The company plans to identify a dose or doses appropriate for further study in a long-term phase 2 efficacy and safety clinical trial, according to a company news release.

The double blind, cross-over test of multiple doses of PYY(3-36) nasal spray includes intravenous PYY and placebo treatment arms. Subjects will be randomized to each treatment arm with about one week between treatments.

Plans are to conclude the $400,000 study during fourth-quarter 2006.

"This study will provide insight into the optimal doses of PYY to reduce food intake," president and chief executive officer Steven C. Quay said in the release.

"With obesity reaching epidemic levels worldwide, the need for a safe and effective product that promotes weight loss has become critically important."

Nastech, located in Bothell, Wash., develops products for multiple therapeutic areas including osteoporosis, diabetes, obesity, respiratory diseases and inflammatory conditions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.